profit from every $100 of sales.
$0$100
Editas Medicine
$2.38-4.99% today
-10.5% in 1 year
1-year low $1.661-year high $3.75
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Editas Medicine sold, what it kept, and what it did with the cash.
Sales went from $19.7 million in 2022 to $40.5 million in 2025, with -$160 million of profit last year.
SalesProfit
Editas Medicine vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Editas Medicine | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Editas Medicine's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 20 | 78 | 32 | 41 | |
| – | – | – | – | |
| -226 | -169 | -239 | -99 | |
| -220 | -163 | -229 | -149 | |
| -220 | -153 | -237 | -160 | |
| -3.21 | -2.02 | -2.88 | -1.80 | |
| – | – | – | – | |
| -1,146.3% | -216.6% | -739.4% | -245.2% | |
| -1,118.3% | -196.1% | -733.7% | -395.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 514 | 499 | 342 | 187 |
| Cash | 142 | 124 | 132 | 147 |
| Total debt | 44 | 37 | 35 | 18 |
| Total liabilities | 154 | 150 | 207 | 159 |
| 361 | 349 | 134 | 27 | |
| 69 | 76 | 82 | 89 | |
| -44.1% | -34.7% | -109.6% | -267.8% | |
| -61.1% | -43.9% | -176.6% | -586.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -177 | -132 | -210 | -165 | |
| 4 | 5 | 9 | 1 | |
| -181 | -137 | -219 | -166 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 29 | 20 | 21 | 10 |
Valuation
- –
- –
- –
- 69.1×
- 9.1×
- –
- –
- -45.1%
- -43.6%
- 0.0%
Profitability
- 100.0%
- -245.2%
- -395.0%
- -213.8%
- -77.5%
- -84.0%
- -677.4%
- -73.0%
- -82.2%
- 184.6%
Growth
- +27.1%
- –
- +24.3%
- –
- +7.0%
Financial health
- -0.9×
- 3.92
- 11.6%
- 40.7×
- 3.22
- 3.22
- 0.24
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 958
Top 20%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.26 | -0.30 | +13.3% |
| Mar 9, 2026 | -0.06 | -0.27 | +77.8% |
| Nov 10, 2025 | -0.28 | -0.38 | +26.3% |
| Aug 12, 2025 | -0.63 | -0.41 | −53.7% |
| May 12, 2025 | -0.43 | -0.51 | +15.7% |
| Mar 5, 2025 | -0.55 | -0.39 | −41.0% |
| Nov 4, 2024 | -0.75 | -0.76 | +1.3% |
| Aug 7, 2024 | -0.82 | -0.69 | −18.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
22No pass
Philip Fisher
53No pass
Peter Lynch
45No pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
49No pass
Questions about Editas Medicine
Is Editas Medicine a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Editas Medicine AI analysis
What does Editas Medicine do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. It is in Biotechnology.
Does Editas Medicine pay a dividend?
No. Editas Medicine does not pay a dividend at the moment.
Is Editas Medicine stock halal?
No. Editas Medicine does not pass our halal screen: its cash and confirmed interest-bearing investments are 40% of its market value, at or above the 33% limit. How we check
How has Editas Medicine stock done over the past year?
Down 10.5% over the past twelve months, to $2.38. It traded between $1.66 and $3.75 and is 36.5% below its high.
Who are Editas Medicine's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Editas Medicine's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.